 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning BioMS Medical Corp.
|
-
Spectral Diagnostics enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
(21 Dec 2009)
Spectral Diagnostics Inc. and BioMS Medical Corp. announced that BioMS Medical and a syndicate of investors have invested $14 million in Spectral Diagnostics to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and ...
-
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
(24 Sep 2008)
US$10 million received based on the positive review of interim analysis for international pivotal multiple sclerosis trial
BioMS Medical Corp. announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the ...
-
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
(15 Aug 2008)
Milestone triggers $10 million payment from Eli Lilly and Company
BioMS Medical Corp. announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 ...
-
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
(05 Aug 2008)
BioMS Medical Corp. announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, ...
-
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
(22 Jul 2008)
BioMS Medical Corp. announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that ...
-
BioMS Medical named Biotech Company of the Year
(13 Jun 2008)
Company to receive Gold Leaf Award from BIOTECanada at BIO 2008
BioMS Medical Corp. announced that it has been selected to receive the Gold Leaf Award from BIOTECanada for "Company of the Year". BioMS Medical will be presented with this distinguished award on June 17, 2008 at the 2008 BIO International ...
-
BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
(14 Nov 2007)
BioMS Medical Corp. announced that more than 133 patients have been enrolled in its MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). An interim safety and efficacy ...
-
BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
(08 Jun 2007)
BioMS Medical Corp announced that the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. The randomized, double-blind study ...
-
BioMS Medical cleared by FDA to initiate pivotal phase III multiple sclerosis trial
(23 Jan 2007)
BioMS Medical Corp announced that it has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use ...
-
BioMS Medical receives additional patent for multiple sclerosis drug MBP8298 in the United States
(06 Nov 2006)
BioMS Medical Corp announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive ...
Additional information
BioMS Medical Corp.
Edmonton, Alberta, Canada
Company
|
|
|
|
|
|
Top
